MedTrace Logo

Clinical Evaluation of the Residual Antimicrobial Activity

NCT04495920 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-08-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the residual antimicrobial efficacy of one test product as defined by the difference between the number of a challenge bacterial species recovered following exposure to the test product and the number recovered when untreated (negative control). The challenge bacterial species to be used is Staphylococcus aureus (ATCC #6538) (S. aureus). Testing will be carried out using a modification of the standardized test method described in ASTM E2752-10 (2015) Standard Guide for Evaluation of Residual Effectiveness of Antibacterial Personal Cleansing Products. Bacterial recoveries will be assayed after application oftest material, using the forearms as a substrate.

Conditions

  • Bacterial Overgrowth

Interventions

DRUG

CGB-S-100

Alcohol and choline geranate

Sponsors & Collaborators

  • BioScience Laboratories, Inc.

    collaborator INDUSTRY

  • CAGE Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Senior Scientist · BIOSCIENCE LAB ORA TORIES, INC.

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2020-07-13
Completion
2020-07-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04495920 on ClinicalTrials.gov